Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.
Hikmat A Al-AhmadieGopakumar V IyerByron H LeeSasinya N ScottRohit MehraAditya BagrodiaEmmet J JordanSizhi Paul GaoRicardo RamirezEugene K ChaNeil B DesaiEmily C ZaborIrina OstrovnayaAnuradha GopalanYing-Bei ChenSamson W FineSatish K TickooAnupama GandhiJoseph HreikiAgnès VialeMaria E ArcilaGuido DalbagniJonathan E RosenbergBernard H BochnerDean F BajorinMichael F BergerVictor E ReuterBarry S TaylorDavid B SolitPublished in: Nature genetics (2016)
Plasmacytoid bladder cancer is an aggressive histologic variant with a high risk of disease-specific mortality. Using whole-exome and targeted sequencing, we find that truncating somatic alterations in the CDH1 gene occur in 84% of plasmacytoid carcinomas and are specific to this histologic variant. Consistent with the aggressive clinical behavior of plasmacytoid carcinomas, which frequently recur locally, CRISPR/Cas9-mediated knockout of CDH1 in bladder cancer cells enhanced cell migration.